Navigation Links
2 Common Blood Pressure Meds Fare Equally in Preventing Heart Woes
Date:8/27/2012

MONDAY, Aug. 27 (HealthDay News) -- In a review that compared two common heart drugs against each other, researchers found no difference between atenolol and metoprolol in terms of preventing stroke, heart attack or heart failure for patients with high blood pressure who were placed on the medications.

Atenolol (Tenormin) and metoprolol tartrate (Lopressor) are beta blockers that are widely used to treat high blood pressure and heart problems. Previous research has suggested that atenolol might be less effective than other high blood pressure drugs for preventing cardiovascular events in patients with high blood pressure.

In this study, researchers reviewed the medical records of nearly 121,000 U.S. patients with high blood pressure but no history of heart disease who started taking one of the two drugs between 2000 and 2009. Atenolol was used by about 10 times more patients than metoprolol.

During a follow-up averaging about five years, there was no statistically significant difference in rates of heart attack, stroke or heart failure between the two groups of patients.

"In conclusion, we found no differences in [heart] event rates ... with either atenolol or metoprolol," said review author Emily Parker, of HealthPartners Institute for Education and Research in Minneapolis, and colleagues. However, the researchers added that the findings "should be interpreted cautiously, since there have been no trials comparing these two beta blockers directly."

Two experts not connected to the study said patients have many options for treating high blood pressure.

"Like many of my colleagues, I also use beta blockers as an add-on antihypertensive strategy for those patients being treated for hypertension and not yet having other cardiac problems," said Dr. David Friedman, chief of heart failure services at North Shore-LIJ's Plainview Hospital, in Plainview, N.Y. He added, however, that "when it comes to treating blood pressure alone, beta blockers have taken a back seat to other medications such as diuretics."

Dr. Kenneth Ong is acting chair of the department of medicine and cardiology at The Brooklyn Hospital Center, in New York City. He noted that there has been debate as to whether atenolol works as well as other drugs used to fight high blood pressure.

"While the [new] study is a retrospective analysis, it suggests that there may be no merit to changing atenolol to metoprolol tartrate," he said. "It will be important to verify these findings with a randomized, prospective trial."

The review was funded by the U.S. National Heart, Lung and Blood Institute, and was published online Aug. 27 in the Archives of Internal Medicine.

More information

The U.S. National Heart, Lung, and Blood Institute has more about treatment of high blood pressure.

-- Robert Preidt

SOURCES: Kenneth Ong, M.D., acting chair, department of medicine and cardiology, The Brooklyn Hospital Center, New York City; David Friedman, M.D., chief, heart failure services, North Shore-LIJ Plainview Hospital, Plainview, N.Y.; Archives of Internal Medicine, news release, Aug. 27, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Obese and overweight women face increased risk of recurrence of most common type of breast cancer
2. Rejected drug may protect against toxic substance common to Alzheimers and Parkinsons diseases
3. Condition Commonly Seen in Aging May Alter Brain Function
4. Alcohol advertising standards violations most common in magazines with youthful audiences
5. No difference in death rates among patients exposed to common rheumatoid arthritis drugs
6. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
7. Diverted Medical Marijuana Use Common Among Teens: Study
8. Asthma Common Among Olympic Athletes
9. Common Skin Cancer a Chronic Condition, Study Says
10. Drug combo better for common type of metastatic breast cancer, UCI-led study finds
11. Asthma is the most common chronic disease among Olympic athletes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
2 Common Blood Pressure Meds Fare Equally in Preventing Heart Woes
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: